Evidence map›Paper›PMID 37896134›Full record

ArticlePharmaceutics2023

Molecular Mechanisms Involved in the Chemical Instability of ONC201 and Methods to Counter Its Degradation in Solution.

Maxime Annereau, Marina Vignes, Lucas Denis, André Rieutord, François-Xavier Legrand, François Rioblanc, Muriel Paul, Jacques Grill, Philippe-Henri Secretan, Bernard Do

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maxime AnnereauUniversité Paris-Saclay, 91400 Orsay, France.ORCID 0000-0001-9594-2516
Marina VignesUniversité Paris-Saclay, 91400 Orsay, France.
Lucas DenisClinical Pharmacy Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
André RieutordClinical Pharmacy Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.ORCID 0000-0001-5935-7635
François-Xavier LegrandUniversité Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France.ORCID 0000-0002-7271-7284
François RioblancClinical Pharmacy Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
Muriel PaulDepartment of Pharmacy, Henri Mondor Hospital, AP-HP, 94000 Creteil, France.
Jacques GrillMolecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France.
Philippe-Henri SecretanUniversité Paris-Saclay, Matériaux et Santé, 91400 Orsay, France.ORCID 0000-0002-5838-3695
Bernard DoUniversité Paris-Saclay, 91400 Orsay, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is one of the most common and aggressive forms of brain tumor, a rare disease for which there is a great need for innovative therapies. ONC201, a new drug substance, has been used in a compassionate treatment program where the choice of dosage form and regimen have yet to be justified. The prior knowledge needed to anticipate ONC201 stability problems has recently been partially addressed, by (i) showing that ONC201 is sensitive to light and oxidation and (ii) identifying the molecular structures of the main degradation products formed. The aim of the work presented here was to improve our understanding of the degradation pathways of ONC201 using data from ab initio calculations and experimental work to supplement the structural information we already published. The C-H bonds located αto the amine of the tetrahydropyridine group and those located

Indexed as

antioxidant effectsDFTONC201oxidation mechanismphotolysis mechanismpreformulation studies

Identifiers

PMID37896134
PMCPMC10609984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.